載入...
Contradictory KRAS mutation test results in a patient with metastatic colon cancer: A clinical dilemma in the era of personalized medicine
The KRAS oncogene is mutated in 40‒50% of colorectal cancers and confers resistance to EGFR-targeted therapy. In the clinic, agents such as cetuximab or panitumumab target the EGFR receptor for therapeutic benefit. Cetuximab was approved by the FDA in 2012 as first-line therapy for KRAS mutation-neg...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Landes Bioscience
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3841208/ https://ncbi.nlm.nih.gov/pubmed/23792572 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.25095 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|